Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Katrina Sweeney"'
Autor:
Colleen C. Nelson, Katrina Sweeney, Meenakshi Malhotra, Brett G. Hollier, Raphael Darcy, Caitriona M. O'Driscoll, James C. Evans
Publikováno v:
International journal of pharmaceutics. 532(1)
The main barrier to the development of an effective RNA interference (RNAi) therapy is the lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the delivery of siRNA. In the present study, a folate-targeted amph
Autor:
Heike Müller, Virginie Adam, Na Ra Kang, Nicholas R. Lemoine, Gunnel Halldén, Maria Ekblad, Katrina Sweeney, Kristina Hammarén Busch, Camilla Tørnqvist Johnsen
Publikováno v:
Human Gene Therapy. 23:1003-1015
AdΔΔ is an oncolytic adenoviral mutant that has been engineered to selectively target tumors with deregulated cell cycle and apoptosis pathways. AdΔΔ potentiates apoptotic cell death induced by drugs, including mitoxantrone and docetaxel, which a
Autor:
Philip A. Gregory, Margaret M. Centenera, Lisa M. Butler, Brett G. Hollier, Rajdeep Das, Nataly Stylianou, Wayne D. Tilley, Scott L. Townley, Adrienne R. Hanson, Amina Zoubeidi, Gregory J. Goodall, Carolina Soekmadji, Katrina Sweeney, Colleen C. Nelson, Isabel Coutinho, Lidija Jovanovic, Luke A. Selth
Publikováno v:
Europe PubMed Central
MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely corre
Autor:
Gunnel Halldén, Celina Costas, Eva Yanover, Virginie Adam, Nicholas R. Lemoine, Daniel Öberg, Katrina Sweeney
Publikováno v:
Clinical Cancer Research. 16:541-553
Purpose: Replication-selective oncolytic adenoviruses are a promising class of tumor-targeting agents with proven safety in hundreds of patients. However, clinical responses have been limited and viral mutants with higher potency are needed. Here, we